Anti-cancer effects of ginsenoside compound k on pediatric acute myeloid leukemia cells

Cancer Cell International

Xiaolin Li¹  Yan Zhu¹  Yajing Xu¹  Yan Chen¹ 

[1] Department of Hematology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, P.R. China

关键词: Pediatric acute myeloid leukemia;    Compound K;    Ginsenoside;   

Others  :  794176
DOI  :  10.1186/1475-2867-13-24

 received in 2013-02-12, accepted in 2013-03-08,  发布年份 2013

【 摘 要 】

Pediatric acute myeloid leukemia (AML) is a heterogeneous disease and remains clinically challenging. Currently chemotherapies are frequently associated with treatment-related death and long-term side effects. Therefore, alternative approaches with lower toxicity are highly desired. Ginsenosides and metabolites are the main ingredients responsible for the multiple pharmaceutical functions of ginseng, which is one of the most commonly consumed herbal medicines world widely. In the present study, we demonstrated that compound K, a major ginsenoside metabolite, inhibited the growth of the clinically relevant pediatric AML cell lines in a time- and dose-dependent manner. This growth inhibitory effect was attributable to suppression of DNA synthesis during cell proliferation. Furthermore, we observed significant G1 cell cycle arrest and apoptosis induced by compound K. The induction of apoptosis was accompanied by DNA double strand breaks. Our findings suggest that as a low toxic natural reagent, compound K could be a potential drug for pediatric AML intervention and to improve the outcome of pediatric AML treatment.

【 授权许可】

   
2013 Chen et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Manola KN: Cytogenetics of pediatric acute myeloid leukemia. Eur J Haematol 2009, 83:391-405.
• [2]Kaspers GJ, Zwaan CM: Pediatric acute myeloid leukemia: towards high-quality cure of all patients. Haematologica 2007, 92:1519-1532.
• [3]Slats AM, Egeler RM, an der Does-van den Berg A: Causes of death--other than progressive leukemia--in childhood acute lymphoblastic (ALL) and myeloid leukemia (AML): the Dutch Childhood Oncology Group experience. Leukemia 2005, 19:537-544.
• [4]Rubnitz JE, Lensing S, Zhou Y: Death during induction therapy and first remission of acute leukemia in childhood: the St. Jude experience. Cancer 2004, 101:1677-1684.
• [5]Creutzig U, Zimmermann M, Reinhardt D, Dworzak M, Stary J, Lehrnbecher T: Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. J Clin Oncol 2004, 22:4384-4393.
• [6]Meshinchi S, Arceci RJ: Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia. Oncologist 2007, 12:341-355.
• [7]O’Hara M, Kiefer D, Farrell K, Kemper K: A review of 12 commonly used medicinal herbs. Arch Fam Med 1998, 7:523-536.
• [8]Jia L, Zhao Y, Liang XJ: Current evaluation of the millennium phytomedicine- ginseng (II): Collected chemical entities, modern pharmacology, and clinical applications emanated from traditional Chinese medicine. Curr Med Chem 2009, 16:2924-2942.
• [9]Jia L, Zhao Y: Current evaluation of the millennium phytomedicine–ginseng (I): etymology, pharmacognosy, phytochemistry, market and regulations. Curr Med Chem 2009, 16:2475-2484.
• [10]Yun TK, Choi SY: Preventive effect of ginseng intake against various human cancers: a case–control study on 1987 pairs. Cancer Epidemiol Biomarkers Prev 1995, 4:401-408.
• [11]Yun TK: Experimental and epidemiological evidence on non-organ specific cancer preventive effect of Korean ginseng and identification of active compounds. Mutat Res 2003, 523–524:63-74.
• [12]Qi LW, Wang CZ, Yuan CS: American Ginseng: Potential structure-function relationship in cancer chemoprevention. Biochem Pharmacol 2010, 80:947-954.
• [13]Choi YJ, Yoon JH, Cha SW, Lee SG: Ginsenoside Rh1 inhibits the invasion and migration of THP-1 acute monocytic leukemia cells via inactivation of the MAPK signaling pathway. Fitoterapia 2011, 82:911-919.
• [14]Cho SH, Chung KS, Choi JH, Kim DH, Lee KT: Compound K, a metabolite of ginseng saponin, induces apoptosis via caspase-8-dependent pathway in HL-60 human leukemia cells. BMC Cancer 2009, 9:449. BioMed Central Full Text
• [15]Lee SJ, Ko WG, Kim JH, Sung JH, Moon CK, Lee BH: Induction of apoptosis by a novel intestinal metabolite of ginseng saponin via cytochrome c-mediated activation of caspase-3 protease. Biochem Pharmacol 2000, 60:677-685.
• [16]Vichai V, Kirtikara K: Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 2006, 1:1112-1116.
• [17]Paull TT, Rogakou EP, Yamazaki V, Kirchgessner CU, Gellert M, Bonner WM: A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. Curr Biol 2000, 10:886-895.
• [18]Yun TK: Brief introduction of Panax ginseng C.A. Meyer. J Korean Med Sci 2001, 16:S3-5.
• [19]Coon JT, Ernst E: Panax ginseng: a systematic review of adverse effects and drug interactions. Drug Saf 2002, 25:323-344.
• [20]Hess FG, Parent RA, Stevens KR, Cox GE, Becci PJ: Effects of subchronic feeding of ginseng extract G115 in beagle dogs. Food Chem Toxicol 1983, 21:95-97.
• [21]Helms S: Cancer prevention and therapeutics: Panax ginseng. Altern Med Rev 2004, 9:259-274.
• [22]Ha YW, Ahn KS, Lee JC, Kim SH, Chung BC, Choi MH: Validated quantification for selective cellular uptake of ginsenosides on MCF-7 human breast cancer cells by liquid chromatography-mass spectrometry. Anal Bioanal Chem 2010, 396:3017-3025.
• [23]Asou H, Tashiro S, Hamamoto K, Otsuji A, Kita K, Kamada N: Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation. Blood 1991, 77:2031-2036.